Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1204rxw

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:21:24 ON 06 JUN 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:21:46 ON 06 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JUN 2008 HIGHEST RN 1025900-65-5
DICTIONARY FILE UPDATES: 5 JUN 2008 HIGHEST RN 1025900-65-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading C:\Documents and Settings\rkeys\My Documents\STNEXP\SCRIPTS\10669404.str





chain nodes :
7 8
ring nodes :
1 2 3 4 5 6
chain bonds :
4-7 7-8
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
4-7
exact bonds :
7-8
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS

L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1

=> d
L2 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L2 QUE L1

=> s l2
SAMPLE SEARCH INITIATED 16:25:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8394 TO ITERATE

23.8% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 162388 TO 173372
PROJECTED ANSWERS: 144561 TO 154935

L3 50 SEA SSS SAM L1

=> d scan

L3 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2(5H)-Furanone, 3-[2,6-difluoro-4-(trifluoromethoxy)phenyl]-5-hydroxy-5-methyl-4-[4-(2-pyridinylthio)phenyl]-
MF C23 H14 F5 N O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d his

(FILE 'HOME' ENTERED AT 16:21:24 ON 06 JUN 2008)

FILE 'REGISTRY' ENTERED AT 16:21:46 ON 06 JUN 2008
L1 STRUCTURE UPLOADED
L2 QUE L1
L3 50 S L2

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.22	3.43

FILE 'CAPLUS' ENTERED AT 16:26:04 ON 06 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 Jun 2008 VOL 148 ISS 24
FILE LAST UPDATED: 5 Jun 2008 (20080605/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l3 and (oled or organic light(2w)emitting diode or photodetector or fluorescent emitter# or phosphorescent emitter#)

```
             4 L3
          5687 OLED
        410793 ORGANIC
       1192772 LIGHT
          5967 ORGANIC LIGHT
                 (ORGANIC(W)LIGHT)
        115220 EMITTING
         97011 DIODE
         18496 EMITTING DIODE
                 (EMITTING(W)DIODE)
          1357 ORGANIC LIGHT(2W)EMITTING DIODE
         10988 PHOTODETECTOR
        185255 FLUORESCENT
         49418 EMITTER#
            55 FLUORESCENT EMITTER#
                 (FLUORESCENT(W)EMITTER#)
          6226 PHOSPHORESCENT
         49418 EMITTER#
           108 PHOSPHORESCENT EMITTER#
                 (PHOSPHORESCENT(W)EMITTER#)
L4             0 L3 AND (OLED OR ORGANIC LIGHT(2W)EMITTING DIODE OR PHOTODETECTOR
                  OR FLUORESCENT EMITTER# OR PHOSPHORESCENT EMITTER#)

=> s l3
L5             4 L3

=> d scan

L5    4 ANSWERS   CAPLUS  COPYRIGHT 2008 ACS on STN
CC   27-16 (Heterocyclic Compounds (One Hetero Atom))
     Section cross-reference(s): 1
TI   Synthesis and Structure-Activity Relationships of 4-Pyridones as Potential
     Antimalarials
ST   pyridinone dihydro aryloxyaryl prepn antimalarial
IT   Structure-activity relationship
        (antimalarial; synthesis and structure-activity relationships of
        1,4-dihydro-4-pyridones as potential antimalarials)
IT   Antimalarials
     Malaria
     Plasmodium berghei yoelii
     Plasmodium falciparum
        (synthesis and structure-activity relationships of 1,4-dihydro-4-
        pyridones as potential antimalarials)
IT   137735-23-0P   137736-01-7P   137755-15-8P
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant
     or reagent)
        (synthesis and structure-activity relationships of 1,4-dihydro-4-
        pyridones as potential antimalarials)
IT   137735-13-8P   137735-14-9P   137735-15-0P   137735-18-3P   137735-24-1P
     137735-25-2P   137735-28-5P   137735-31-0P   137735-48-9P   137735-49-0P
     137735-52-5P   137735-68-3P   137735-83-2P   137735-84-3P   137736-02-8P
     137736-04-0P   1023961-41-2P   1023961-42-3P   1023961-43-4P
     1023961-44-5P   1023961-47-8P   1023961-48-9P   1023961-50-3P
     1023961-52-5P   1023961-73-0P   1023961-74-1P   1023961-75-2P
     1023961-76-3P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
     (Biological study); PREP (Preparation)
        (synthesis and structure-activity relationships of 1,4-dihydro-4-
        pyridones as potential antimalarials)
```

IT 79-24-3, Nitroethane 98-56-6, 4-Chlorobenzotrifluoride 103-79-7, Benzyl methyl ketone 106-41-2, 4-Bromophenol 106-48-9, 4-Chlorophenol 108-22-5, Isopropenyl acetate 112-12-9, 2-Undecanone 118-71-8 123-54-6, 2,4-Pentanedione, reactions 123-75-1, Pyrrolidine, reactions 371-41-5, 4-Fluorophenol 431-47-0, Methyl trifluoroacetate 459-57-4, 4-Fluorobenzaldehyde 680-15-9 828-27-3, 4-(Trifluoromethoxy)phenol 5586-88-9 19393-11-4, Potassium acetylacetonate, reactions 21906-31-0 21906-32-1 23055-77-8 37595-74-7, N-Phenylbis(trifluoromethanesulfonimide) 49708-81-8 103962-05-6, 1-Iodo-4-(trifluoromethoxy)benzene 164522-90-1 441354-26-3 1023961-33-2 1023961-49-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis and structure-activity relationships of 1,4-dihydro-4-pyridones as potential antimalarials)

IT 40122-80-3P 61343-99-5P 101960-96-7P 121804-19-1P 137735-12-7P 137735-16-1P 137735-29-6P 137735-47-8P 137735-50-3P 137735-51-4P 137735-66-1P 137735-82-1P 137736-06-2P 137736-08-4P 137736-10-8P 137736-11-9P 137736-12-0P 137736-13-1P 137736-14-2P 137736-18-6P 137736-26-6P 137736-27-7P 137736-28-8P 137736-29-9P 137736-30-2P 137736-33-5P 137736-34-6P 137736-40-4P 137736-41-5P 137736-42-6P 137736-56-2P 137736-60-8P 137736-61-9P 137755-19-2P 138642-48-5P 873203-36-2P 934842-04-3P 958457-41-5P 1023961-32-1P 1023961-34-3P 1023961-35-4P 1023961-36-5P 1023961-37-6P 1023961-38-7P 1023961-39-8P 1023961-40-1P 1023961-45-6P 1023961-46-7P 1023961-54-7P 1023961-56-9P 1023961-58-1P 1023961-60-5P 1023961-62-7P 1023961-64-9P 1023961-66-1P 1023961-68-3P 1023961-69-4P 1023961-70-7P 1023961-71-8P 1023961-72-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and structure-activity relationships of 1,4-dihydro-4-pyridones as potential antimalarials)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L5 4 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
TI Preparation of substituted pyrazoles as kinase inhibitors, and their compositions and use for treatment of cancer
ST pyrazole prepn FAK Tie2 KDR kinase inhibitor neoplasm
IT Antitumor agents
Human
Neoplasm
(preparation of pyrazoles as KDR and Tie2 kinase inhibitors and their use for treating cancer)

IT 1024498-73-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of pyrazoles as KDR and Tie2 kinase inhibitors and their use for treating cancer)

IT 1024498-71-2P 1024498-74-5P 1024498-77-8P 1024498-80-3P 1024498-83-6P 1024498-86-9P 1024498-89-2P 1024498-92-7P 1024498-95-0P 1024498-98-3P 1024499-00-0P 1024499-03-3P 1024499-06-6P 1024499-09-9P 1024499-12-4P 1024499-15-7P 1024499-18-0P 1024499-21-5P 1024499-24-8P 1024499-27-1P 1024499-30-6P 1024499-33-9P 1024499-36-2P 1024499-39-5P 1024499-42-0P 1024499-45-3P 1024499-48-6P 1024499-51-1P 1024499-54-4P 1024499-57-7P 1024499-60-2P 1024499-62-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(drug candidate; preparation of pyrazoles as KDR and Tie2 kinase inhibitors and their use for treating cancer)

IT 148047-29-4, Tie2 kinase 150977-45-0, KDR kinase 372092-80-3
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; preparation of pyrazoles as KDR and Tie2 kinase inhibitors and their use for treating cancer)

IT 6952-67-6P
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrazoles as KDR and Tie2 kinase inhibitors and their use for treating cancer)

IT 67221-50-5DP, resin bound 945003-95-2P, 1-(3-Formylphenyl)-3-(4-trifluoromethylphenyl)urea 1024498-75-6P, 1-(2-Fluoro-5-trifluoromethylphenyl)-3-(3-formylphenyl)urea 1024498-78-9P, 1-(2-Fluorophenyl)-3-(3-formylphenyl)urea 1024498-81-4P, 1-(2-Methoxyphenyl)-3-(3-formylphenyl)urea 1024498-84-7P, 1-(2-Fluoro-3-trifluoromethylphenyl)-3-(3-formylphenyl)urea 1024498-87-0P, 1-(3-Methoxyphenyl)-3-(3-formylphenyl)urea 1024498-90-5P, 1-(3-Fluoro-5-trifluoromethylphenyl)-3-(3-formylphenyl)urea 1024498-93-8P, 1-(4-Trifluoromethoxyphenyl)-3-(3-formylphenyl)urea 1024498-96-1P, 1-(3-Methoxycarbonylphenyl)-3-(3-Formylphenyl)urea 1024499-01-1P, 1-(3-Formylphenyl)-3-(3-trifluoromethylphenyl)urea 1024499-04-4P, 1-(3-Formylphenyl)-3-(2-trifluoromethylphenyl)urea 1024499-07-7P, 1-(3-Formylphenyl)-3-(3,5-dimethoxyphenyl)urea 1024499-10-2P, 1-(3-Formylphenyl)-3-(3-tolyl)urea 1024499-13-5P, 1-(3-Formylphenyl)-3-(4-methoxyphenyl)urea 1024499-16-8P, 1-(3-Formylphenyl)-3-(4-fluorophenyl)urea 1024499-19-1P, 1-(3-Formylphenyl)-3-(3-trifluoromethyl-4-chlorophenyl)urea 1024499-22-6P, 1-(3-Formylphenyl)-3-[4-(difluoromethoxy)phenyl]urea 1024499-25-9P, 1-(3-Formylphenyl)-3-(2-chloro-4-trifluoromethylphenyl)urea 1024499-28-2P, 1-(3-Formylphenyl)-3-(4-tolyl)urea 1024499-31-7P, 1-(3-Formylphenyl)-3-(2,5-dimethylphenyl)urea 1024499-34-0P, 1-(3-Formylphenyl)-3-(3,4-dimethylphenyl)urea 1024499-37-3P, 1-(3-Formylphenyl)-3-(2-tolyl)urea 1024499-40-8P, 1-(3-Formylphenyl)-3-(3-ethylphenyl)urea 1024499-43-1P, 1-(3-Formylphenyl)-3-[3,5-bis(trifluoromethyl)phenyl]urea 1024499-46-4P, 1-(3-Formylphenyl)-3-(3-fluorophenyl)urea 1024499-49-7P, 1-(3-Formylphenyl)-3-(2-methoxy-5-methylphenyl)urea 1024499-52-2P, 1-(3-Formylphenyl)-3-(2,5-dimethoxyphenyl)urea 1024499-55-5P, 1-(3-Formylphenyl)-3-[3-chloro-4-(difluoromethoxy)phenyl]urea 1024499-58-8P, 1-(3-Formylphenyl)-3-(2,5-difluorophenyl)urea
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrazoles as KDR and Tie2 kinase inhibitors and their use for treating cancer)

IT 99-61-6, 3-Nitrobenzaldehyde 327-78-6, 4-Chloro-3-trifluoromethylphenyl isocyanate 329-01-1, 3-Trifluoromethylphenyl isocyanate 404-71-7, 3-Fluorophenyl isocyanate 614-68-6, 2-Tolyl isocyanate 621-29-4, 3-Tolyl isocyanate 622-58-2, 4-Tolyl isocyanate 700-87-8, 2-Methoxyphenyl isocyanate 1195-45-5, 4-Fluorophenyl isocyanate 1548-13-6, 4-Trifluoromethylphenyl isocyanate 1709-44-0, 3-Aminobenzaldehyde 2285-12-3, 2-Trifluoromethylphenyl isocyanate 5334-40-7, 4-Nitro-3-pyrazolecarboxylic acid 5416-93-3, 4-Methoxyphenyl isocyanate 16588-74-2, 3,5-Bis(trifluoromethyl)phenyl isocyanate 16744-98-2, 2-Fluorophenyl isocyanate 18908-07-1, 3-Methoxyphenyl isocyanate 23138-58-1, 3-Ethylphenyl isocyanate 29734-16-5, Aminobenzaldehyde 35037-73-1, 4-Trifluoromethoxyphenyl isocyanate 37070-87-4, Phenylcarbamic acid 3-formylphenyl ester 39479-97-5, 3-Chloro-4-difluoromethoxyphenyl isocyanate 39718-32-6,

2,5-Difluorophenyl isocyanate 40397-98-6, 2,5-Dimethylphenyl isocyanate 41221-47-0, 3-Isocyanatobenzoic acid methyl ester 51163-27-0, 3,4-Dimethylphenyl isocyanate 51488-22-3, 2-Chloro-4-trifluoromethylphenyl isocyanate 51903-64-1, 4-Methyl-3-trifluoromethylphenyl isocyanate 54132-76-2, 3,5-Dimethoxyphenyl isocyanate 56309-62-7, 2,5-Dimethoxyphenyl isocyanate 58417-15-5, 4-Difluoromethoxyphenyl isocyanate 59741-04-7, 2-Methoxy-5-methylphenyl isocyanate 69922-27-6, 2-Fluoro-5-trifluoromethylphenyl isocyanate 190774-52-8, 2-Fluoro-3-trifluoromethylphenyl isocyanate 302912-19-2, 3-Fluoro-5-trifluoromethylphenyl isocyanate 360056-45-7, 4-Amino-3-pyrazolecarboxylic acid methyl ester
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazoles as KDR and Tie2 kinase inhibitors and their use for treating cancer)

L5 4 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
TI Preparation of benzimidazole derivatives as CRF receptor antagonists
ST benzimidazole prepn CRF receptor antagonist antidepressant anxiolytics affective disorder
IT Mental and behavioral disorders
(affective; preparation of benzimidazole derivs. as CRF receptor antagonists)
IT Mental and behavioral disorders
(depression; preparation of benzimidazole derivs. as CRF receptor antagonists)
IT Antidepressants
Anxiety
Anxiolytics
Human
(preparation of benzimidazole derivs. as CRF receptor antagonists)
IT Corticotropin releasing factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of benzimidazole derivs. as CRF receptor antagonists)
IT 1022251-47-3P, 5-Chloro-2-[[5-chloro-7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-yl]oxy]benzenesulfonamide
RL: BYP (Byproduct); PREP (Preparation)
(preparation of benzimidazole derivs. as CRF receptor antagonists)
IT 1022251-57-5P 1022251-61-1P 1022251-64-4P 1022251-82-6P
RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazole derivs. as CRF receptor antagonists)
IT 1022248-73-2P, 2-[2-Bromo-4-(trifluoromethoxy)phenoxy]-7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazole 1022248-99-2P, 2-(2-Bromo-4,6-dichlorophenoxy)-4-chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-15-5P, 2-(4-Bromo-2-chloro-6-methylphenoxy)-4-chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-17-7P, 3-Chloro-4-[[4-chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazol-2-yl]oxy]-5-methylbenzonitrile 1022249-21-3P, 4-Chloro-2-[2-chloro-6-methyl-4-(methylthio)phenoxy]-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-31-5P, 2-[2-Bromo-6-chloro-4-(trifluoromethoxy)phenoxy]-4-chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-33-7P, 4-Chloro-2-[2-chloro-6-(methylthio)-4-(trifluoromethoxy)phenoxy]-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-38-2P, 4-Chloro-7-(1-ethylpropyl)-N-[2-methoxy-6-methyl-4-(methylthio)phenyl]-1-methyl-1H-benzimidazol-2-amine 1022249-46-2P, N-(2-Bromo-4-chloro-6-methylphenyl)-4-chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazol-2-amine 1022249-49-5P, 4-Chloro-N-[4-chloro-2-methyl-6-(methylthio)phenyl]-7-(1-

ethylpropyl)-1-methyl-1H-benzimidazol-2-amine 1022249-68-8P 1022249-82-6P, 4-Chloro-2-[2,6-dichloro-4-(trifluoromethoxy)phenoxy]-7-(1-ethylpropyl)-1-[2-[(4-methoxybenzyl)oxy]ethyl]-1H-benzimidazole 1022249-87-1P, 4-Bromo-2-(2,4-dichloro-6-methylphenoxy)-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-93-9P, 4-Chloro-2-[(4,6-dibromo-2-methylpyridin-3-yl)oxy]-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-99-5P, 1-[3,5-Dichloro-2-[[7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-yl]oxy]phenyl]-N,N-dimethylmethanamine 1022250-03-8P, 2-[2,4-Dichloro-6-[(pyrrolidin-1-yl)methyl]phenoxy]-7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazole 1022250-05-0P, 2-[2,4-Dichloro-6-[(2-methylpyrrolidin-1-yl)methyl]phenoxy]-7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazole 1022250-13-0P, 1-[2-[[4-Chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazol-2-yl]oxy]-3-methyl-5-(trifluoromethoxy)phenyl]-N,N-dimethylmethanamine 1022250-28-7P, 1-[4-Chloro-2-(2,4-dichloro-6-methylphenoxy)-1-methyl-1H-benzimidazol-7-yl]propan-1-one 1022250-29-8P, 4-Chloro-2-(2,4-dichloro-6-methylphenoxy)-1-methyl-7-(1-methylenepropyl)-1H-benzimidazole 1022250-30-1P, 2-[4-Chloro-2-(2,4-dichloro-6-methylphenoxy)-1-methyl-1H-benzimidazol-7-yl]butan-1-ol 1022250-32-3P, 2-[4-Chloro-2-(2,4-dichloro-6-methylphenoxy)-1-methyl-1H-benzimidazol-7-yl]butanal 1022250-33-4P, 4-Chloro-2-(2,4-dichloro-6-methylphenoxy)-7-(1-ethylprop-2-en-1-yl)-1-methyl-1H-benzimidazole 1022250-34-5P, 3-[4-Chloro-2-(2,4-dichloro-6-methylphenoxy)-1-methyl-1H-benzimidazol-7-yl]pentan-1-ol 1022250-36-7P, 3-[4-Chloro-2-(2,4-dichloro-6-methylphenoxy)-1-methyl-1H-benzimidazol-7-yl]pentanal 1022250-45-8P, 1-[2-[[7-(1-Ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-yl]oxy]-3-methyl-5-(trifluoromethoxy)phenyl]-N,N-dimethylmethanamine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzimidazole derivs. as CRF receptor antagonists)

IT 913299-91-9P, 3,5-Dichloro-4-[[7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-yl]oxy]-N,N-dimethylaniline 1022248-57-2P, 2-[2-Chloro-4-(trifluoromethoxy)phenoxy]-7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazole 1022248-60-7P, 3-Chloro-4-[[7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-yl]oxy]-N,N-dimethylaniline 1022248-62-9P, 5-Chloro-2-[[7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-yl]oxy]-N,N-dimethylaniline 1022248-64-1P, 3-[[7-(1-Ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-yl]oxy]-N,N-dimethyl-6-methylpyridin-2-amine 1022248-65-2P, 1-[4-[[7-(1-Ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-yl]oxy]-3-methylphenyl]ethanone 1022248-68-5P, 3,5-Dichloro-2-[[7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-yl]oxy]-N,N-dimethylaniline 1022248-69-6P, 2-[(5-Bromo-3-methylpyridin-2-yl)oxy]-7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazole 1022248-72-1P, 1-[5-Chloro-2-[[7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-yl]oxy]phenyl]-N,N-dimethylmethanamine 1022248-75-4P, 7-(1-Ethylpropyl)-4-methoxy-1-methyl-2-[[6-methyl-2-(trifluoromethyl)pyridin-3-yl]oxy]-1H-benzimidazole 1022248-79-8P, 2-[[7-(1-Ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-yl]oxy]-N,N-dimethyl-5-(trifluoromethyl)aniline 1022248-80-1P, 1-[2-[[7-(1-Ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-yl]oxy]-5-(trifluoromethoxy)phenyl]-N,N-dimethylmethanamine 1022248-82-3P, 7-(1-Ethylpropyl)-4-methoxy-1-methyl-2-[(1,4,5-trimethyl-1H-pyrazol-3-yl)oxy]-1H-benzimidazole 1022248-83-4P, 1-[2-[[7-(1-Ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-yl]oxy]-3-methyl-5-(trifluoromethoxy)phenyl]-N,N-dimethylmethanamine Hydrochloride 1022248-87-8P, N-[2-Chloro-4-(trifluoromethyl)phenyl]-7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-amine 1022248-88-9P, N-[4-Chloro-2-(trifluoromethyl)phenyl]-7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-amine 1022248-90-3P, N-[2-Chloro-4-(trifluoromethoxy)phenyl]-7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-

benzimidazol-2-amine 1022248-91-4P, N-(2-Bromo-4-chlorophenyl)-7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-amine 1022248-92-5P, N-(2,4-Dichlorophenyl)-7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-amine 1022248-95-8P, 4-Chloro-N-[7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-yl]-N',N'-dimethylbenzene-1,2-diamine 1022248-98-1P, 5-Chloro-2-[[7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-yl]oxy]benzenesulfonamide 1022249-00-8P, 3,5-Dichloro-2-[[4-chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazol-2-yl]oxy]-N,N-dimethylaniline 1022249-02-0P, 4-Chloro-2-[2,4-dichloro-6-(morpholin-4-yl)phenoxy]-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-05-3P, 4-Chloro-2-[2,4-dichloro-6-(4-methylpiperazin-1-yl)phenoxy]-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-07-5P, 4-Chloro-2-[2,4-dichloro-6-(1H-imidazol-1-yl)phenoxy]-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-09-7P, 3,5-Dichloro-2-[[4-chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazol-2-yl]oxy]-N-methylaniline 1022249-10-0P, 4-Chloro-2-[2,4-dichloro-6-(pyrrolidin-1-yl)phenoxy]-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-11-1P, 2-[[7-(1-Ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-yl]oxy]-N,N-dimethyl-5-(trifluoromethoxy)aniline 1022249-12-2P, 3,5-Dichloro-2-[[4-chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazol-2-yl]oxy]benzonitrile 1022249-13-3P, 3,5-Dichloro-2-[[4-chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazol-2-yl]oxy]benzenesulfonamide 1022249-18-8P, 1-[3-Chloro-4-[[4-chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazol-2-yl]oxy]-5-methylphenyl]ethanone 1022249-22-4P, 4-Chloro-2-[2-chloro-6-methyl-4-(methylsulfinyl)phenoxy]-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-25-7P, 4-Chloro-2-[2-chloro-6-methyl-4-(methylsulfonyl)phenoxy]-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-27-9P, 3-Chloro-4-[[4-chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazol-2-yl]oxy]-5-methylbenzamide 1022249-29-1P, 3-Chloro-4-[[4-chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazol-2-yl]oxy]-5-methylbenzenesulfonamide 1022249-34-8P, 4-Chloro-2-[2-chloro-6-(methylsulfinyl)-4-(trifluoromethoxy)phenoxy]-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-35-9P, 4-Chloro-2-[2-chloro-6-(methylsulfonyl)-4-(trifluoromethoxy)phenoxy]-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-41-7P, 4-Chloro-7-(1-ethylpropyl)-N-[2-methoxy-6-methyl-4-(methylsulfinyl)phenyl]-1-methyl-1H-benzimidazol-2-amine 1022249-42-8P, 4-Chloro-7-(1-ethylpropyl)-N-[2-methoxy-6-methyl-4-(methylsulfonyl)phenyl]-1-methyl-1H-benzimidazol-2-amine 1022249-44-0P, 4-[[4-Chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazol-2-yl]amino]-3-methoxy-5-methylbenzamide 1022249-50-8P, 4-Chloro-N-[4-chloro-2-methyl-6-(methylsulfinyl)phenyl]-7-(1-ethylpropyl)-1-methyl-1H-benzimidazol-2-amine 1022249-51-9P, 3-[[4-Chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazol-2-yl]oxy]-4-methoxy-N,N-dimethyl-6-methylpyridin-2-amine 1022249-54-2P 1022249-57-5P, 4-Chloro-7-(1-ethylpropyl)-1-methyl-2-[(2-methyl-2,3-dihydro-1H-isoindol-4-yl)oxy]-1H-benzimidazole 1022249-58-6P, 4-Chloro-2-[(5,7-dichloro-2-methyl-2,3-dihydro-1H-isoindol-4-yl)oxy]-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-59-7P, 4-Chloro-7-(1-ethylpropyl)-2-[[4-methoxy-2-methyl-6-(trifluoromethyl)pyridin-3-yl]oxy]-1-methyl-1H-benzimidazole 1022249-62-2P, 4-Chloro-7-(1-ethylpropyl)-N-[2-methoxy-6-methyl-4-(1H-pyrazol-1-yl)phenyl]-1-methyl-1H-benzimidazol-2-amine 1022249-63-3P, 4-Chloro-7-(1-ethylpropyl)-N-[2-methoxy-6-methyl-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-methyl-1H-benzimidazol-2-amine 1022249-66-6P, 4-Chloro-2-[2-chloro-6-methyl-4-(trimethylsilyl)phenoxy]-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-67-7P, 4-Chloro-2-[2,4-dichloro-6-(trimethylsilyl)phenoxy]-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-71-3P, N-(4-Chloro-2-methoxy-6-methylphenyl)-7-[1-(dimethylamino)propyl]-1-methyl-1H-benzimidazol-2-amine 1022249-72-4P, 2-[4-Bromo-2-(2,4-dichloro-6-methylphenoxy)-7-(1-ethylpropyl)-1H-benzimidazol-1-yl]-N,N-dimethylethanamine 1022249-75-7P,

4-Chloro-2-(2,4-dichloro-6-methylphenoxy)-7-(1-ethylpropyl)-1H-benzimidazole 1022249-77-9P, 4-Chloro-2-[2,6-dichloro-4-(trifluoromethoxy)phenoxy]-7-(1-ethylpropyl)-1H-benzimidazole 1022249-79-1P, 4-Chloro-N-(2,4-dichloro-6-methylphenyl)-7-(1-ethylpropyl)-1H-benzimidazol-2-amine 1022249-80-4P, 4-Chloro-N-(4-chloro-2-methoxy-6-methylphenyl)-7-(1-ethylpropyl)-1H-benzimidazol-2-amine 1022249-85-9P, 2-[4-Chloro-2-[2,6-dichloro-4-(trifluoromethoxy)phenoxy]-7-(1-ethylpropyl)-1H-benzimidazol-1-yl]ethanol 1022249-88-2P, 2-(2,4-Dichloro-6-methylphenoxy)-4-ethyl-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-89-3P, 2-(2-Bromo-4-chlorophenoxy)-4-ethoxy-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-92-8P, 2-(2,4-Dichloro-6-methylphenoxy)-4-ethoxy-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-96-2P, 2-[[4-Bromo-2-methyl-6-(trifluoromethyl)pyridin-3-yl]oxy]-4-chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022249-97-3P, 4-Chloro-7-(1-ethylpropyl)-1-methyl-2-[[2-methyl-4,6-bis(trifluoromethyl)pyridin-3-yl]oxy]-1H-benzimidazole 1022250-01-6P, 4-Chloro-2-[2,4-dichloro-6-[(pyrrolidin-1-yl)methyl]phenoxy]-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022250-06-1P, 2-(4-Bromo-2-chloro-6-fluorophenoxy)-7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazole 1022250-09-4P, 7-(1-Ethylpropyl)-2-[2-(1H-imidazol-1-yl)-4-(trifluoromethoxy)phenoxy]-4-methoxy-1-methyl-1H-benzimidazole 1022250-11-8P, 3-Chloro-4-[[4-chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazol-2-yl]oxy]-N,N-dimethylaniline 1022250-14-1P, 1-[2-[[4-Chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazol-2-yl]oxy]-3-methyl-5-(trifluoromethoxy)phenyl]-N,N-dimethylmethanamine Hydrochloride 1022250-17-4P, 1-[3,5-Dichloro-2-[[4-chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazol-2-yl]oxy]phenyl]-N,N-dimethylmethanamine 1022250-19-6P, 3-Chloro-4-[[7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-yl]oxy]-N,N-dimethyl-5-[(pyrrolidin-1-yl)methyl]aniline 1022250-21-0P, N-(2,4-Dichloro-6-methylphenyl)-7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-amine 1022250-22-1P, N-[2,6-Dichloro-4-(trifluoromethoxy)phenyl]-7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-amine 1022250-24-3P, 2-[(2,4-Dichloro-6-methylphenyl)amino]-7-(1-ethylpropyl)-1-methyl-1H-benzimidazol-4-ol 1022250-26-5P, 2-(2,4-Dichloro-6-methylphenoxy)-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022250-39-0P, 3-[4-Chloro-2-(2,4-dichloro-6-methylphenoxy)-1-methyl-1H-benzimidazol-7-yl]pentanoic acid 1022250-41-4P, 2-[4-Chloro-2-[(2,4-dichlorophenyl)amino]-7-(1-ethylpropyl)-1H-benzimidazol-1-yl]ethanol 1022250-42-5P, 2-[4-Chloro-2-[[4-chloro-2-[(dimethylamino)methyl]phenyl]amino]-7-(1-ethylpropyl)-1H-benzimidazol-1-yl]ethanol 1022250-44-7P, 1-[2-[2,6-Dichloro-4-(trifluoromethoxy)phenoxy]-1-methyl-1H-benzimidazol-7-yl]-N,N-dimethylpropan-1-amine 1022250-58-3P, 1-[3,5-Dichloro-2-[[7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazol-2-yl]oxy]phenyl]-N,N-dimethylmethanamine hydrochloride 1022251-40-6P, 2-[2,4-Dichloro-6-[(pyrrolidin-1-yl)methyl]phenoxy]-7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazole hydrochloride 1022251-68-8P 1022251-84-8P, 2-[2,4-Dichloro-6-[(2-methylpyrrolidin-1-yl)methyl]phenoxy]-7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazole hydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazole derivs. as CRF receptor antagonists)

IT 913299-59-9P, 2-(2-Bromo-4-chlorophenoxy)-7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazole 1022251-75-7P, 1-[2-[2,6-Dichloro-4-(trifluoromethoxy)phenoxy]-1-methyl-1H-benzimidazol-7-yl]propan-1-one 1022251-78-0P, 1-[2-[2,6-Dichloro-4-(trifluoromethoxy)phenoxy]-1-methyl-1H-benzimidazol-7-yl]-N-methylpropan-1-amine 1022251-80-4P 1022251-87-1P
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzimidazole derivs. as CRF receptor antagonists)
IT 95-85-2, 2-Amino-4-chlorophenol 105-13-5, 4-Methoxybenzyl alcohol 105-36-2, Ethyl bromoacetate 109-01-3, 1-Methylpiperazine 110-70-3, N,N'-Dimethylethylenediamine 110-91-8, Morpholine, reactions 120-83-2, 2,4-Dichlorophenol 123-75-1, Pyrrolidine, reactions 288-13-1, Pyrazole 288-32-4, 1H-Imidazole, reactions 321-14-2, 5-Chlorosalicylic acid 445-03-4, 4-Chloro-2-trifluoromethylaniline 554-00-7, 2,4-Dichloroaniline 609-14-3, Ethyl 2-methylacetoacetate 609-89-2, 2,4-Dichloro-6-nitrophenol 611-10-9, Ethyl 2-oxocyclopentanecarboxylate 615-65-6, 2-Chloro-4-methylaniline 695-96-5, 2-Bromo-4-chlorophenol 700-37-8, 4-Chloro-2-fluoro-1-nitrobenzene 765-38-8, 2-Methylpyrrolidine 824-94-2, 4-Methoxybenzyl chloride 873-38-1, 2-Bromo-4-chloroaniline 876-02-8, 1-[4-Hydroxy-3-methylphenyl]ethanone 1118-02-1, Trimethylsilyl isocyanate 1121-25-1, 2-Methylpyridin-3-ol 1570-65-6, 2,4-Dichloro-6-methylphenol 3964-52-1, 4-Amino-2-chlorophenol 3970-35-2, 2-Chloro-3-nitrobenzoic acid 4524-77-0, 2-Bromo-4,6-dichlorophenol 4584-46-7, 2-Dimethylaminoethyl chloride hydrochloride 5930-28-9, 4-Amino-2,6-dichlorophenol 7530-27-0, 4-Bromo-2-chloro-6-methylphenol 15128-90-2, 6-Methyl-2-nitropyridin-3-ol 20154-03-4, 3-(Trifluoromethyl)-1H-pyrazole 23003-30-7, 2-Iodo-6-methylpyridin-3-ol 29921-57-1, Isopropyl bromoacetate 30273-00-8, 2,4-Dichloro-6-methylaniline 37418-88-5, 4-Hydroxy-2-benzofuran-1,3-dione 39885-50-2, 2-Chloro-4-trifluoromethylaniline 50868-73-0, 2-Methoxy-6-methylaniline 60639-52-3, N'-Methylbenzene-1,2,3-triamine 69695-61-0, 2-Chloro-4-trifluoromethoxyaniline 70783-75-4, 2-Chloro-4-(trifluoromethoxy)phenol 89488-30-2, 5-Bromo-3-methyl-2-hydroxypyridine 99479-66-0, 2,6-Dichloro-4-(trifluoromethoxy)aniline 161045-79-0, 4-Bromo-2-chloro-6-fluorophenol 200956-13-4, 2-Bromo-4-(trifluoromethoxy)phenol 704884-79-7, [2-Hydroxy-5-(trifluoromethoxy)phenyl]-N,N-dimethylmethanamine 913297-45-7, 7-Bromo-N-(4-chloro-2-methoxy-6-methylphenyl)-1-methyl-1H-benzimidazol-2-amine 913298-57-4, N-(4-Bromo-2-methoxy-6-methylphenyl)-4-chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazol-2-amine 913298-94-9, 2-(2,4-Dichloro-6-methylphenoxy)-4-chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 913299-07-7, 4-(1-Ethylpropyl)-1,3-dihydro-2H-benzimidazol-2-one 913299-08-8, tert-Butyl 4-(1-ethylpropyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxylate 933673-43-9, 2-[(Dimethylamino)methyl]-6-methyl-4-(trifluoromethoxy)phenol 1022251-43-9, N,N-Dimethyl-2-hydroxy-5-(trifluoromethyl)aniline 1022251-70-2, 2-Chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022251-72-4, 4-Chloro-2-[(dimethylamino)methyl]aniline
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzimidazole derivs. as CRF receptor antagonists)
IT 527-62-8P, 2-Amino-4,6-dichlorophenol 3740-31-6P, 4-Hydroxy-2-methyl-1H-isoindole-1,3(2H)-dione 17826-77-6P, 1,4,5-Trimethyl-1H-pyrazol-3-ol 20348-16-7P, 2-Amino-6-methylpyridin-3-ol 30427-17-9P, 4-Chloro-2-(dimethylamino)phenol 41213-40-5P, 2-Methyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-ol 53553-14-3P, Methyl 2-chloro-3-nitrobenzoate 54828-00-1P, 4-Chloro-2-[(dimethylamino)methyl]phenol 56733-61-0P, 2,4-Dichloro-6-[(dimethylamino)methyl]phenol 70112-21-9P, 5-Chloro-2-hydroxy-N,N-dimethylbenzamide 72619-96-6P 82966-07-2P, 2,6-Dichloro-4-(dimethylamino)phenol 96994-74-0P, 5-Chloro-N,N-dimethyl-2-nitroaniline 100127-14-8P, 2,4-Dichloro-6-[(pyrrolidin-1-yl)methyl]phenol 102794-02-5P, 2,6-Dichloro-4-(trifluoromethoxy)phenol 111633-67-1P, 2-Chloro-4-(dimethylamino)phenol 146948-68-7P, 2-Bromo-4-chloro-6-methylaniline 188923-75-3P, 4,6-Dibromo-2-methylpyridin-3-ol 348169-39-1P, 4-Bromo-2-methoxy-6-methylaniline 644961-69-3P 851886-92-5P, 7-Amino-1-methyl-1,3-dihydro-2H-benzimidazol-2-one 851889-13-9P, Methyl 3-methyl-2-oxo-2,3-dihydro-1H-benzimidazole-4-

carboxylate 913297-15-1P 913297-16-2P 913297-43-5P, 7-Bromo-2-chloro-1-methyl-1H-benzimidazole 913297-44-6P, 7-Bromo-1-methyl-1,3-dihydro-2H-benzimidazol-2-one 913298-58-5P, 7-(1-Ethyl-1-hydroxypropyl)-1-methyl-1,3-dihydro-2H-benzimidazol-2-one 913298-59-6P, 7-(1-Ethylpropyl)-1-methyl-1,3-dihydro-2H-benzimidazol-2-one 913298-60-9P, 4-Chloro-7-(1-ethylpropyl)-1-methyl-1,3-dihydro-2H-benzimidazol-2-one 913298-61-0P, 2,4-Dichloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 913298-98-3P, 7-(1-Ethylpropyl)-4-methoxy-1-methyl-1,3-dihydro-2H-benzimidazol-2-one 913298-99-4P, 4-Bromo-7-(1-ethylpropyl)-1-methyl-1,3-dihydro-2H-benzimidazol-2-one 913299-00-0P, 2-Chloro-7-(1-ethylpropyl)-4-methoxy-1-methyl-1H-benzimidazole 913299-10-2P, Isopropyl 2-[7-(1-ethylpropyl)-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl]acetate 913299-11-3P, Isopropyl 2-[4-chloro-7-(1-ethylpropyl)-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl]acetate 913299-12-4P, Isopropyl 2-[2,4-dichloro-7-(1-ethylpropyl)-1H-benzimidazol-1-yl]acetate 913299-16-8P, Methyl 7-chloro-3-methyl-2-oxo-2,3-dihydro-1H-benzimidazole-4-carboxylate 913299-73-7P 1022250-47-0P, 2,4-Dichloro-6-(dimethylamino)phenol 1022250-52-7P, 2-(Dimethylamino)-6-methylpyridin-3-ol 1022250-56-1P, 3-Hydroxy-6-methyl-2-(trifluoromethyl)pyridine 1022250-60-7P, 4-Chloro-N',N'-dimethylbenzene-1,2-diamine 1022250-64-1P, 2-Bromo-6-chloro-4-(trifluoromethoxy)phenol 1022250-65-2P, 2-(Dimethylamino)-4-methoxy-6-methylpyridin-3-ol 1022250-67-4P, 4-Bromo-6-methyl-2-nitropyridin-3-ol 1022250-68-5P, 2-Amino-4-methoxy-6-methylpyridin-3-ol 1022250-70-9P, 4-Methoxy-6-methyl-2-nitropyridin-3-ol 1022250-74-3P, 2-Methylisoindolin-4-ol 1022250-76-5P, 5,7-Dichloro-2-methylisoindolin-4-ol 1022250-78-7P, 4-Methoxy-2-methyl-6-(trifluoromethyl)pyridin-3-ol 1022250-81-2P, 4-Bromo-2-methyl-6-(trifluoromethyl)pyridin-3-ol 1022250-83-4P, 2-Methoxy-6-methyl-4-(1H-pyrazol-1-yl)aniline 1022250-85-6P, 2-Methoxy-6-methyl-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]aniline 1022250-90-3P, 2-[4-Bromo-2-chloro-7-(1-ethylpropyl)-1H-benzimidazol-1-yl]-N,N-dimethylethanamine 1022250-91-4P, 4-(1-Ethylpropyl)-1-(4-methoxybenzyl)-1,3-dihydro-2H-benzimidazol-2-one 1022250-92-5P, 3-[2-(Dimethylamino)ethyl]-4-(1-ethylpropyl)-1-(4-methoxybenzyl)-1,3-dihydro-2H-benzimidazol-2-one 1022250-93-6P, 1-[2-(Dimethylamino)ethyl]-7-(1-ethylpropyl)-1,3-dihydro-2H-benzimidazol-2-one 1022250-95-8P, 4-Bromo-1-[2-(dimethylamino)ethyl]-7-(1-ethylpropyl)-1,3-dihydro-2H-benzimidazol-2-one 1022250-98-1P, 2,4-Dichloro-7-(1-ethylpropyl)-1H-benzimidazole 1022251-00-8P, tert-Butyl 4-(1-ethylpropyl)-3-(4-methoxybenzyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxylate 1022251-01-9P, 7-(1-Ethylpropyl)-1-(4-methoxybenzyl)-1,3-dihydro-2H-benzimidazol-2-one 1022251-03-1P, 4-Chloro-7-(1-ethylpropyl)-1-(4-methoxybenzyl)-1,3-dihydro-2H-benzimidazol-2-one 1022251-06-4P, 2,7-Dichloro-4-(1-ethylpropyl)-1-(4-methoxybenzyl)-1H-benzimidazole 1022251-08-6P, 2,4-Dichloro-7-(1-ethylpropyl)-1-[2-[(4-methoxybenzyl)oxy]ethyl]-1H-benzimidazole 1022251-09-7P, tert-Butyl 3-(2-ethoxy-2-oxoethyl)-4-(1-ethylpropyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxylate 1022251-11-1P, Ethyl 2-[7-(1-ethylpropyl)-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl]acetate 1022251-12-2P, Ethyl 2-[4-chloro-7-(1-ethylpropyl)-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl]acetate 1022251-15-5P, Ethyl 2-[2,4-dichloro-7-(1-ethylpropyl)-1H-benzimidazol-1-yl]acetate 1022251-17-7P, 2-[2,4-Dichloro-7-(1-ethylpropyl)-1H-benzimidazol-1-yl]ethanol 1022251-19-9P, 4-Bromo-2-chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022251-20-2P, 2-Chloro-4-ethoxy-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 1022251-21-3P, 4-Ethoxy-7-(1-ethylpropyl)-1-methyl-1,3-dihydro-2H-benzimidazol-2-one 1022251-25-7P, 2,4-Dichloro-6-[(2-methylpyrrolidin-1-yl)methyl]phenol 1022251-27-9P, 2-Chloro-4-(dimethylamino)-6-[(pyrrolidin-1-yl)methyl]phenol 1022251-29-1P, 1-(2,4-Dichloro-1-methyl-1H-benzimidazol-7-yl)propan-1-one

1022251-30-4P, 7-Chloro-3-methyl-2-oxo-2,3-dihydro-1H-benzimidazole-4-carboxamide 1022251-31-5P, 7-Chloro-3-methyl-2-oxo-2,3-dihydro-1H-benzimidazole-4-carbonitrile 1022251-32-6P, 4-Chloro-1-methyl-7-propionyl-1,3-dihydro-2H-benzimidazol-2-one 1022251-49-5P, 3-Chloro-4-[[4-chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazol-2-yl]oxy]-5-methylbenzoic acid 1022251-54-2P, 2-[(4-Chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazole-7-carbonitrile 1022251-55-3P, 1-[2-[(4-Chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]propan-1-one 1022251-63-3P, 7-Chloro-2-(2,4-dichloro-6-methylphenoxy)-4-(1-ethylpropyl)-1-(4-methoxybenzyl)-1H-benzimidazole 1022251-71-3P, Ethyl 2-[4-chloro-2-[(2,4-dichlorophenyl)amino]-7-(1-ethylpropyl)-1H-benzimidazol-1-yl]acetate 1022251-73-5P, 2-[2,6-Dichloro-4-(trifluoromethoxy)phenoxy]-1-methyl-1H-benzimidazole-7-carbonitrile
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzimidazole derivs. as CRF receptor antagonists)

L5 4 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
CC 27-10 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 5
TI Preparation of trifluoromethoxyphenyl tetramic acids as agrochemical insecticides
ST trifluoromethoxyphenyl tetramic acid prepn agrochem myzus persicae
IT Agrochemicals
Insecticides
Myzus persicae
(preparation of trifluoromethoxyphenyl tetramic acids as agrochem. insecticides)
IT 81-84-5, 1H,3H-Naphtho[1,8-cd]pyran-1,3-dione 93-65-2 94-74-6 94-75-7, biological studies 94-82-6 122-88-3 1918-00-9 3547-07-7 3740-92-9 7064-04-2 21409-25-6 22052-63-7 31541-57-8 39089-45-7 41295-28-7 41858-19-9 42609-52-9 52836-31-4 54091-06-4 61432-55-1 71526-07-3 72850-64-7 74782-23-3 79660-25-6 85072-82-8 88349-90-0 88485-37-4 97454-00-7 98730-04-2 99485-76-4 99607-70-2 99621-31-5 103112-35-2 116572-67-9 118286-11-6 119515-19-4 120347-16-2 121776-33-8 126067-40-1 126099-96-5 126099-98-7 129513-09-3 129513-55-9 129531-12-0 133607-95-1 133993-74-5 135439-10-0 135590-91-9 143341-17-7 143341-18-8 146893-26-7 154502-05-3 154879-67-1 154879-69-3 163520-33-0 163520-46-5 221667-31-8 221667-37-4 724746-82-1 724746-87-6
RL: AGR (Agricultural use); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)
(formulations with; preparation of trifluoromethoxyphenyl tetramic acids as agrochem. insecticides)
IT 1021854-58-9P 1021854-60-3P 1021854-62-5P 1021854-63-6P 1021854-65-8P 1021854-67-0P 1021854-69-2P 1021854-71-6P 1021854-73-8P 1021854-75-0P 1021854-76-1P 1021854-78-3P 1021854-80-7P 1021854-82-9P 1021854-84-1P 1021854-86-3P 1021854-88-5P 1021854-90-9P 1021854-92-1P 1021854-93-2P 1021854-95-4P 1021854-97-6P 1021854-99-8P 1021855-01-5P 1021855-03-7P 1021855-05-9P 1021855-07-1P 1021855-09-3P 1021855-11-7P 1021855-13-9P 1021855-15-1P 1021855-17-3P 1021855-19-5P 1021855-21-9P 1021855-23-1P 1021855-25-3P 1021855-27-5P 1021855-29-7P 1021855-31-1P 1021855-33-3P 1021855-35-5P 1021855-37-7P 1021855-39-9P 1021855-41-3P 1021855-43-5P 1021855-45-7P 1021855-47-9P 1021855-49-1P 1021855-51-5P 1021855-53-7P 1021855-55-9P 1021855-57-1P 1021855-59-3P 1021855-61-7P 1021855-63-9P 1021855-65-1P

1021855-67-3P 1021855-69-5P 1021855-71-9P 1021855-73-1P
1021855-76-4P 1021855-78-6P 1021855-81-1P 1021855-83-3P
1021855-85-5P 1021855-87-7P 1021855-89-9P 1021855-91-3P
1021855-93-5P 1021855-95-7P 1021855-97-9P 1021855-99-1P
1021856-01-8P 1021856-03-0P 1021856-05-2P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of trifluoromethoxyphenyl tetramic acids as agrochem. insecticides)

IT 1021857-01-1P 1021857-03-3P
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of trifluoromethoxyphenyl tetramic acids as agrochem. insecticides)

IT 75-35-4, Vinylidene chloride, reactions 79-30-1, 2-Methylpropionyl chloride 541-41-3, Ethyl chloroformate 99479-66-0, 2,6-Dichloro-4-trifluoromethoxyaniline 199330-66-0, 4-Aminotetrahydropyran-4-carboxylic acid methyl ester hydrochloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of trifluoromethoxyphenyl tetramic acids as agrochem. insecticides)

IT 886503-16-8P 1021856-07-4P 1021856-09-6P 1021856-11-0P
1021856-13-2P 1021856-15-4P 1021856-17-6P 1021856-19-8P
1021856-21-2P 1021856-23-4P 1021856-25-6P 1021856-27-8P
1021856-29-0P 1021856-31-4P 1021856-33-6P 1021856-35-8P
1021856-37-0P 1021856-39-2P 1021856-41-6P 1021856-43-8P
1021856-46-1P 1021856-48-3P 1021856-50-7P 1021856-52-9P
1021856-54-1P 1021856-56-3P 1021856-58-5P 1021856-60-9P
1021856-62-1P 1021856-64-3P 1021856-66-5P 1021856-68-7P
1021856-70-1P 1021856-72-3P 1021856-74-5P 1021856-76-7P
1021856-78-9P 1021856-81-4P 1021856-83-6P 1021856-85-8P
1021856-87-0P 1021856-89-2P 1021856-91-6P 1021856-93-8P
1021856-95-0P 1021856-97-2P 1021856-99-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of trifluoromethoxyphenyl tetramic acids as agrochem. insecticides)

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 16:21:24 ON 06 JUN 2008)

FILE 'REGISTRY' ENTERED AT 16:21:46 ON 06 JUN 2008
L1 STRUCTURE UPLOADED
L2 QUE L1
L3 50 S L2

FILE 'CAPLUS' ENTERED AT 16:26:04 ON 06 JUN 2008
L4 0 S L3 AND (OLED OR ORGANIC LIGHT(2W)EMITTING DIODE OR PHOTODETEC
L5 4 S L3

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.32	33.75

10/669,404

STN INTERNATIONAL LOGOFF AT 16:37:41 ON 06 JUN 2008